About Sunshine Guojian Pharmaceutical Company

The company is one of the first in China to focus on innovative antibody drug research and continues to actively innovate. It has a mature platform integrating research, production and marketing, and focuses on new technology research such as monoclonal antibodies, double antibodies, multiple antibodies and multifunctional recombinant proteins. The company's main business is R&D, production and sales of antibody drugs, and has an independent and complete product R&D, procurement, production and sales system. The company's main products: Exaipu (recombinant human type II tumor necrosis factor receptor-antibody fusion protein), cyptine (injectable initumab), and Genitumab (recombinant anti-CD25 humanized monoclonal antibody injection). The company has a national engineering research center for antibody drugs, and has received support for major national scientific research projects such as 8 national “major new drug creation” major science and technology projects, 4 national high-tech research and development plans (“863 plans”), 3 national strategic emerging industry development special fund plans, 1 national independent innovation and high-tech industrialization project, 1 national high-tech industry development project plan, and 1 national major scientific and technological achievement transformation project.